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Over half of regular consumers of tobacco, including
many young people state a desire to break from tobacco
dependence, but very few succeed in the long term.
OBJECTIVES: The objectives of the program can be
summed up as follows: to contribute to improving public
health knowledge; to understand the progress made by
smokers and ex-smokers; to anticipate success factors in
smoking cessation.
METHODS: In May 2001, 5000 user questionnaires
were distributed by GPs and pharmacists to smokers (S)
or ex-smokers (ES). The questionnaire included the most
frequently used tests, a socio-demographic profile, the in-
dividual’s smoking experience and a questionnaire of
knowledge of the smoking environment.
RESULTS: Presented here is the outcome of the analysis of
the first 700 responses, permitting a better understanding
of how smokers progress when they break from tobacco
dependence. The male/female ratio between smokers
(42%/58%) and ex-smokers (57%/43%) is statistically
significant (p  0.01), both for age (S/ES  39/46yrs) and
weight (S/ES  66/71kg). Forty three percent of ES said
they had a regular sporting activity as opposed to 26% of
S (p  0.001). The daily consumption of a cup of coffee
was different (S/ES  4.1/2.7) (p0.0001). There was no
difference with respect to alcohol consumption. Both
groups complained of being exposed to passive smoke:
S/ES  44%/41%. Forty-seven percent of the smokers
said they had a history of depressive problems, as opposed
to 36% of the former smokers p  0.02.
CONCLUSION: These first results confirm the growing
proportion of women who are tobacco dependent, the in-
fluence of passive smoking and the progress of the
smoker when he or she becomes an ex-smoker.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (Actos *NF) in combination therapy for patients
with type 2 diabetes in Finland.
METHODS: A published, validated model for type1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics (Palmer et al., 2000) was
adapted to simulate long-term (80 years or until death)
management, health outcomes, resource utilisation and
treatment costs of patients with type2 diabetes. The
model accounts for most complications occurring in dia-
betes patients: nephropathy; retinopathy; acute myocar-
dial infarction; angina pectoris; stroke, and amputation.
The analysis was done from third-party-payer perspective
and costs figured relative to the year 2000. A 5% dis-
count rate was applied to costs and outcomes and sensi-
tivity analysis was performed to test the results.
RESULTS: Pioglitazone (PIO) 30 mg and metformin
(MF) were associated with longer life expectancy (15.16
years) than sulphonylureas (SU)/MF (14.47) or rosiglita-
zone (RSG) 8 mg/MF (15.06). PIO 30 mg/SU and PIO15
mg/SU are associated with the lowest number of serious
complications per 100 patients treated. For every 21 pa-
tients treated with PIO 30 mg/MF rather than SU/MF or
every 41 patients, respectively, for PIO15 mg/SU rather
MF/SU one complication is avoided. Combinations of
PIO 30 mg/SU, PIO 30 mg/MF and PIO 15 mg/SU are as-
sociated with lower mortality than the other treatment
combinations available. Thus, for every 35 patients
treated with PIO 30 mg/MF rather than SU/MF one
death will be avoided after 15 years of treatment.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and may
represent a cost-effective use of scarce resources. It is nec-
essary to confirm the results of this theoretical model
once long-term effectiveness data with the compared al-
ternatives are available.
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OBJECTIVE: We assessed the incidence of diabetes in an
ambulatory population treated for the first time with ei-
ther olanzapine or risperidone.
METHODS: We conducted a population-based cohort
study using data from the Quebec drug benefit plan. In-
cluded in the cohort, all people who received a first pre-
scription of olanzapine or risperidone between 1/1/1997
and 8/31/1999, who were eligible for the drug plan, had
not been prescribed an antidiabetic drug or any atypical
antipsychotic for the six-month period preceding the first
olanzapine or risperidone prescription. Person-months of
follow-up were calculated as the amount of time from the
date of the first olanzapine or risperidone prescription to
the date of the first antidiabetic drug prescription. Those
who had a prescription for an antidiabetic drug were
considered as having diabetes. Subjects who discontinued
olanzapine or risperidone, who became non-eligible for
the drug plan and those who reached the end of the fol-
low-up period (8/31/2000) were censored at the event
date. We used a proportional hazard model to compute
the age- and sex-adjusted incidence-rate ratio (IRR) of
having diabetes among olanzapine users compared to ris-
peridone users.
